Biomea Fusion, Inc. financial data

Symbol
BMEA on Nasdaq
Industry
Pharmaceutical Preparations
Location
900 Middlefield Road, 4 Th Floor, Redwood City, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Jul 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 721 % -18.2%
Debt-to-equity 20 % +22.7%
Return On Equity -91.9 % -22.9%
Return On Assets -76.6 % -19.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.2M shares +1.62%
Common Stock, Shares, Outstanding 36.2M shares +1.56%
Entity Public Float 597M USD +133%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 36M shares +1.97%
Weighted Average Number of Shares Outstanding, Diluted 36M shares +1.97%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.07B USD 0%
Research and Development Expense 122M USD +43.1%
General and Administrative Expense 26.6M USD +19.1%
Operating Income (Loss) -148M USD -38.1%
Net Income (Loss) Attributable to Parent -140M USD -36.7%
Earnings Per Share, Basic -3.9 USD/shares -17.5%
Earnings Per Share, Diluted -3.9 USD/shares -17.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 113M USD -49.2%
Assets, Current 116M USD -48.5%
Property, Plant and Equipment, Net 4.45M USD -25.7%
Operating Lease, Right-of-Use Asset 8.32M USD -33.5%
Other Assets, Noncurrent 6.75M USD +72.7%
Assets 136M USD -45.2%
Accounts Payable, Current 5.83M USD +40.3%
Employee-related Liabilities, Current 3.81M USD +32.7%
Liabilities, Current 25.2M USD +75.3%
Operating Lease, Liability, Noncurrent 7.05M USD -29.6%
Liabilities 32.2M USD +32.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1K USD +90%
Retained Earnings (Accumulated Deficit) -325M USD -75.3%
Stockholders' Equity Attributable to Parent 104M USD -53.7%
Liabilities and Equity 136M USD -45.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32M USD -33.2%
Net Cash Provided by (Used in) Financing Activities 116K USD -42.3%
Net Cash Provided by (Used in) Investing Activities -35K USD +98%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 36.2M shares +1.56%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -31.9M USD -24.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 114M USD -49.1%
Deferred Tax Assets, Valuation Allowance 71.5M USD +161%
Deferred Tax Assets, Gross 74.6M USD +167%
Operating Lease, Liability 11.1M USD -16.9%
Depreciation 1.64M USD +61.3%
Payments to Acquire Property, Plant, and Equipment 35K USD -98.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -140M USD -36.7%
Lessee, Operating Lease, Liability, to be Paid 15.3M USD -18.8%
Property, Plant and Equipment, Gross 7.72M USD +1.96%
Operating Lease, Liability, Current 3.29M USD +21.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.53M USD -44.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.9M USD -28.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.23M USD -23.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.44M USD +4.57%
Deferred Tax Assets, Operating Loss Carryforwards 31.5M USD +160%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.22M USD +255%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.47M USD +3.01%
Operating Lease, Payments 2.27M USD +66%
Additional Paid in Capital 429M USD +4.71%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.04M USD +469%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%